Atlas Trials

Rifaximin as a Modulator of Microbial Translocation and Immune Activation

Clinical trial NCT01466595 · COMPLETED

Trial details

NCT number
NCT01466595
Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HIV-1 Infection
Start date
2011-09-01
Primary completion
2012-09-01
Enrollment
73

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.